Overexpressed XRCC2 as an independent risk factor for poor prognosis in glioma patients.
Overexpressed XRCC2 as an independent risk factor for poor prognosis in glioma patients.
复制标题
XRCC2过表达是胶质瘤患者预后不良的独立危险因素
DOI：
10.1186/s10020-021-00316-0
复制
发表时间：
2021-05-29
期刊：
影响因子：
--
通讯作者：
Gao Y
中科院分区：
文献类型：
--
作者：
Liu Z;Zhang W;Cheng X;Wang H;Bian L;Wang J;Han Z;Wang Y;Lian X;Liu B;Ren Z;Zhang B;Jiang Z;Lin Z;Gao Y
XRCC 2是一种同源重组相关基因，已被报道与多种癌症相关。但其在胶质瘤中的作用尚未见报道。本研究旨在通过对数千例脑胶质瘤标本的分析，了解XRCC 2在脑胶质瘤中的作用，揭示XRCC 2参与了哪些脑胶质瘤特异性的生物学过程，从而为脑胶质瘤的治疗和预后评估提供新的视角。 综合分析CGGA和TCGA数据库中数千例胶质瘤标本中XRCC 2的表达特征。采用Wilcox或Kruskal检验分析不同临床和分子特征胶质瘤中XRCC 2的表达模式。Kaplan-Meier和考克斯回归分析XRCC 2对胶质瘤患者预后的影响。基因集富集分析（GSEA）揭示了XRCC 2在胶质瘤中可能的细胞机制。利用连接图（CMap）筛选靶向XRCC 2的小分子药物，RT-qPCR和免疫组化染色检测XRCC 2在胶质瘤细胞和组织中的表达水平。我们发现XRCC 2在胶质瘤中过表达。此外，过表达的XRCC 2与多种与预后相关的临床特征相关。考克斯分析和荟萃分析显示XRCC 2是胶质瘤预后不良的独立危险因素。此外，GSEA的结果表明，过表达的XRCC 2可以通过参与的信号通路，如在细胞周期中促进恶性进展。最后，多沙唑嗪，quinostatin，刀豆氨酸和白杨素被鉴定为通过靶向XRCC 2发挥抗胶质瘤作用。本研究利用多个数据集分析XRCC 2在胶质瘤中的表达模式及其与预后的关系。这是第一项研究表明，XRCC 2是一种新的癌基因，在胶质瘤中显著过表达，并可能导致胶质瘤患者预后不良。XRCC 2可作为胶质瘤诊断、治疗和预后评估的新生物标志物，从而为胶质瘤的管理带来新的见解。在线版本包含补充材料，可通过10.1186/s10020-021-00316-0获得。
XRCC2, a homologous recombination-related gene, has been reported to be associated with a variety of cancers. However, its role in glioma has not been reported. This study aimed to find out the role of XRCC2 in glioma and reveal in which glioma-specific biological processes is XRCC2 involved based on thousands of glioma samples, thereby, providing a new perspective in the treatment and prognostic evaluation of glioma. The expression characteristics of XRCC2 in thousands of glioma samples from CGGA and TCGA databases were comprehensively analyzed. Wilcox or Kruskal test was used to analyze the expression pattern of XRCC2 in gliomas with different clinical and molecular features. The effect of XRCC2 on the prognosis of glioma patients was explored by Kaplan–Meier and Cox regression. Gene set enrichment analysis (GSEA) revealed the possible cellular mechanisms involved in XRCC2 in glioma. Connectivity map (CMap) was used to screen small molecule drugs targeting XRCC2 and the expression levels of XRCC2 were verified in glioma cells and tissues by RT-qPCR and immunohistochemical staining. We found the overexpression of XRCC2 in glioma. Moreover, the overexpressed XRCC2 was associated with a variety of clinical features related to prognosis. Cox and meta-analyses showed that XRCC2 is an independent risk factor for the poor prognosis of glioma. Furthermore, the results of GSEA indicated that overexpressed XRCC2 could promote malignant progression through involved signaling pathways, such as in the cell cycle. Finally, doxazosin, quinostatin, canavanine, and chrysin were identified to exert anti-glioma effects by targeting XRCC2. This study analyzed the expression pattern of XRCC2 in gliomas and its relationship with prognosis using multiple datasets. This is the first study to show that XRCC2, a novel oncogene, is significantly overexpressed in glioma and can lead to poor prognosis in glioma patients. XRCC2 could serve as a new biomarker for glioma diagnosis, treatment, and prognosis evaluation, thus bringing new insight into the management of glioma. The online version contains supplementary material available at 10.1186/s10020-021-00316-0.
登录
查看更多内容
影响因子：
19
作者：
Ceccaldi R;Rondinelli B;D'Andrea AD
通讯作者：
D'Andrea AD
使用 XRCC2 启动子进行体内癌症诊断和治疗。
影响因子：
9
作者：
Chen Y;Li Z;Xu Z;Tang H;Guo W;Sun X;Zhang W;Zhang J;Wan X;Jiang Y;Mao Z
通讯作者：
Mao Z
影响因子：
11
作者：
Huang, Hsiao-Chieh;Liu, Wei-Ting;Gean, Po-Wu
通讯作者：
Gean, Po-Wu
XRCC2中的遗传变异：对结直肠癌肿瘤发生的新见解。
DOI：
10.1158/1055-9965.epi-09-0187
发表时间：
2009-09
期刊：
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
影响因子：
--
作者：
Curtin K;Lin WY;George R;Katory M;Shorto J;Cannon-Albright LA;Smith G;Bishop DT;Cox A;Camp NJ;Colorectal Cancer Study Group
通讯作者：
Colorectal Cancer Study Group
XRCC1 多态性与神经胶质瘤风险之间的关联：病例对照研究的荟萃分析
影响因子：
3.7
作者：
Jiang L;Fang X;Bao Y;Zhou JY;Shen XY;Ding MH;Chen Y;Hu GH;Lu YC
通讯作者：
Lu YC